drugset

drugset / Trial / NCT02475109

Study of Topical Ocular PAN-90806 in PDR

NCT02475109 ↗

Phase 1 Completed 10 enrolled PanOptica, Inc.

NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to assess the safety and tolerability of topical ocular PAN-90806 in patients with proliferative diabetic retinopathy.

Timeline

Start: 2015-08
Primary completion: 2016-05
Completion: 2016-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	OSI-632	Small molecule	—	Topical

Indications